A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.

NCT00730847 · clinicaltrials.gov ↗
PHASE4
Phase
TERMINATED
Status
743
Enrollment
INDUSTRY
Sponsor class

Stopped GSK received exemption from PDFDA on conduct of this post-marketing surveillance (PMS) study.

Conditions

Interventions

Sponsor

GlaxoSmithKline